hereditary breast cancer
Conditions
Interventions
None listed
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -IVF/PGD treatment for a BRCA1/2-mutation, both male and female mutation carriers (Control group A and Test group, respectively) -IVF/PGD treatment because the male partner has an autosomal dominant hereditary disorder (such as but not restricted to Huntingtons disease or Marfan syndrome) or both male/female partners carry a autosomal recessive hereditary disorder (such as but not restricted to cystic fibrosis or spinal muscular atrophy )(Control group B)
Exclusion criteria
Exclusion criteria: - Known hereditary disease other than due to BRCA1/2-mutations in the female - Known genetic abnormalities in female leading to diminished ovarian reserve: carriers of fragile X syndrome or abnormalities of the X-chromosome - Hereditary disease in male known to affect embryo development - Known history of a malignancy in the female - Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or renal) - History of cancer treatment in the female or male - Non-Dutch couples, not able to understand the patient information to give informed consent properly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Morphology, the presence of apoptosis, DNA damage and chromosomal aberrations in the (im)mature oocytes and embryos of BRCA1/2-mutation carriers compared to oocytes and embryos of controls. | — |
Countries
Netherlands
Outcome results
None listed